Context: Abnormal angiogenesis plays an important role in pathogenesis of diabetic kidney disease (DKD). Leucine-rich a-2 glycoprotein 1 (LRG1) is a newly identified angiogenic factor.
(microalbuminuria) as the earliest clinical manifestation of incipient DKD, followed by progression to a large amount of urinary albumin loss (macroalbuminuria) and finally renal function decline (1) . However, it should be emphasized that DKD is a heterogeneous disease in terms of its clinical manifestation and natural course, especially in patients with type 2 diabetes mellitus (T2DM) (1, 2) . A subpopulation of patients with diabetes may progress to impaired renal function without having proceeding albuminuria (1, 4) .
Leucine-rich a-2 glycoprotein 1 (LRG1) was identified as a serum protein in 1977 (5) . Its structure is characterized by a marked periodicity in leucine residues, which enables it to be involved in protein-protein interactions (6) . Although its biological functions remain unknown in the past decades, increases in plasma LRG1 levels have been reported in several diseases. For this reason, LRG1 has been proposed as a biomarker for cancer (7, 8) , neurodegenerative disease (9) , and heart failure (10) . Expression of LRG1 in liver may be upregulated by lipopolysaccharide and by mediators of acute-phase response such as interleukin 6. Therefore, LRG1 may also be a potential acute-phase protein and inflammation marker (11) . In agreement, elevation of plasma LRG1 level has been observed in inflammatory diseases (12) (13) (14) . Notably, a recent study has identified LRG1 as a novel proangiogenic factor (15) . Protein level of LRG1 was found to be elevated in the vitreous body of proliferative diabetic retinopathy patients, and its expression in vascular tissue was increased during neovascular growth. LRG1 promotes endothelial cell proliferation and migration by binding directly to transforming growth factor-b (TGF-b) accessory receptor endoglin, which, in the presence of TGF-b, enhances the activation of the proangiogenic Smad1/5/8 signaling pathway (15) .
Of note, recent studies have also associated LRG1 with kidney diseases. Plasma LRG1 level was higher in patients with chronic kidney disease (CKD) compared with those with preserved renal function (16). Moreover, a higher level of plasma LRG1 was associated with an increased risk for mortality in patients with hemodialysis (16) . In addition, a higher level of urine LRG1 has been observed in patients with immunoglobulin A nephropathy (17) . In our early cross-sectional study, we reported that plasma LRG1 level was inversely correlated with estimated glomerular filtration rate (eGFR) and positively correlated with albuminuria level in patients with T2DM (18) .
Although risk for DKD progression is often associated with a long diabetes duration, poor control of hyperglycemia, hypertension, and dyslipidemia, its underlying pathophysiologic mechanisms are still incompletely understood (1, 19) . Metabolic flux-induced loss of microvascular endothelial cells and local hypoxia in the kidney may be compensated by abnormal angiogenesis, which is characterized by growth of fragile small blood vessels (20, 21) . Biopsy in patients with diabetes and studies in animal models have suggested that abnormal glomerular neovascularization may be involved in the pathogenesis and progression of DKD (22) (23) (24) .
Given the roles of LRG1 in neovascularization and inflammation, as well as its correlation with kidney dysfunction in early studies, we postulate that LRG1 may be involved in the pathogenesis and progression of DKD in patients with T2DM (25, 26) . In the current work, our main aim is to study whether plasma LRG1 may predict risk for DKD progression in patients with T2DM in a 3-year prospective study.
Materials and Methods

Study population
Participant recruitment for the Singapore Study of Macroangiopathy and Micro-vascular Reactivity in Type 2 Diabetes cohort has been described in details elsewhere (18, 27) . Briefly, 2058 adult participants (21 years and older) with T2DM were recruited from a secondary hospital and a community medical center in the northern part of Singapore from August 2011 to March 2014. Three years after enrollment date, participants were recalled consecutively for the current follow-up study. The study has been approved by the Singapore National Health Group Domain Specific Review Board, and written consent has been obtained from each participant.
Clinical and biochemical variables
Collection of baseline data and biospecimens has been described in details elsewhere (18) . Briefly, blood pressure was measured by an automated blood pressure monitor, and the average of three readings was used. Blood and urine (spot urine) specimens were collected after an overnight fast. Serum triacylglycerol and high-density lipoprotein and low-density lipoprotein cholesterol were measured by enzymatic methods (Roche Cobas Integra 700; Roche Diagnostics, Basel, Switzerland). Hemoglobin A1c (HbA1c) was measured by a point-of-care immunoassay analyzer (DCA Vantage Analyzer; Siemens, Munich, Germany). Plasma C-reactive protein (CRP) was measured by an immunoassay kit according to the manufacturer's instruction (R&D Systems, Minneapolis, MN). Measurements of creatinine and urine albumin were performed in the same clinical laboratory for both enrollment and follow-up studies. Creatinine was quantified by an enzymatic method that was traceable to isotope dilution mass spectrometry reference. Urinary albumin was measured based on a solid-phase competitive chemiluminescent immunoassay (Immulite; DPC, Gwynedd, UK). Albuminuria level was presented as an albuminto-creatinine ratio (ACR, mg/g). Glomerular filtration rate was estimated by the Chronic Kidney Disease Epidemiology Collaboration equation (28) . Plasma and urine LRG1 levels were measured by a sandwich enzyme-linked immunosorbent assay kit (Immuno-Biological Laboratories, Hamburg, Germany). Urine LRG1 concentration was normalized to 1 mM urine creatinine. The intra-assay coefficient of variation was 3.0% to 4.9%, interassay coefficient of variation was 4.2% to 5.1%, and sensitivity was 0.17 mg/mL. Data and biospecimen collections for enrollment and this 3-year follow up were performed by same team of research nurses.
Definitions of albuminuria progression and CKD progression
Albuminuria levels were categorized as normal to mildly elevated (ACR ,30 mg/g, "normoalbuminuria"), moderately elevated (ACR 30 to 299 mg/g, "microalbuminuria"), or severely elevated (ACR .300 mg/g, "macroalbuminuria") (2, 29) . Albuminuria progression was defined as increment in urine albumin loss to a higher category (normoalbuminuria to microalbuminuria or macroalbuminuria; microalbuminuria to macroalbuminuria), whereas regression was defined as a microalbuminuria to normoalbuminuria transition. Participants with macroalbuminuria at baseline (n = 158) were excluded from analysis of albuminuria progression (30) .
CKD progression (rapid eGFR decline) was defined as decline of eGFR from baseline by 40% or greater in 3 years. This end point has recently been recommended as an alternative end point for CKD progression (31) . Participants with eGFR changes within 620% range in the follow-up duration were taken as controls. This is because the eGFR can deviate from measured glomerular filtration rate up to 30%; also, participants with a 20% eGFR change have a relatively lower risk for ESRD and mortality (29, 31) .
Statistical analysis
Continuous data are presented as mean 6 standard deviation (SD) or median (interquartile range, IQR). Categorical data are presented as proportions. Plasma LRG1, triacylglycerol, CRP, urine ACR, and urine LRG1 were natural logarithmically transformed due to their skewed distribution. Group differences in clinical and biochemical variables were compared by Student t test, one-way analysis of variance, or x 2 test where appropriate. Multivariable linear regression models were used to examine which clinical and biochemical variables were independently associated with plasma and urine LRG1 at the cross-sectional level, respectively.
Binary multivariable logistic regression models were used to study the association of plasma and urine LRG1 levels with albuminuria and CKD progression, respectively. ACR or CKD progression (yes or no) was entered as dependent variables, respectively. Standardized natural log-transformed LRG1 was entered as the main independent variable. Age, sex, ethnicity, smoking, duration of T2DM, body mass index (BMI), systolic blood pressure (SBP), HbA1c, and lipids profile were included as covariates. The models were further adjusted for baseline eGFR and ACR, the key risk factors and markers for DKD progression, as well as usage of insulin and renin-angiotensin system antagonists. Given that plasma LRG1 level is correlated with the systemic inflammation marker CRP, log-transformed CRP was also adjusted in the full model.
Sensitivity analyses were applied to examine the robustness of the association of baseline plasma LRG1 with albuminuria progression. (1) In total, 180 participants with three ACR readings collected separately within 6 months before or after enrollment and another three ACR readings collected 6 months before or after the follow-up date were included for a subanalysis. The average of three readings at baseline and followup was calculated, respectively, to determine albuminuria progression. (2) Participants with albuminuria regression were excluded from the control group in the albuminuria progression analysis. (3) Participants were stratified by normoalbuminuria and microalbuminuria according to baseline ACR levels. Normoalbuminuria to microalbuminuria and microalbuminuria to macroalbuminuria progression were analyzed separately.
C-statistics was used to evaluate whether adding plasma LRG1 may improve the predictive performance of traditional biomarkers. We used integrated discrimination improvement to measure the separation between progressor and nonprogressor in terms of average predicted risk (32) . We applied continuous net reclassification improvement to calculate the sum of the net percentages of subjects with and without progression being correctly assigned a different predicted risk (33) .
Statistical analysis was performed by SPSS (version 22) and R software (version 3.2.3). A two-sided P , 0.05 level was considered as statistically significant.
Results
Association of plasma LRG1 with baseline clinical and biochemical characteristics
In total, 1226 participants with T2DM were included in the current study (Supplemental Fig. 1 ). Participants who refused, were lost to follow-up, or died were older and more likely on insulin treatment. They had a longer diabetes duration and poorer renal function (Supplemental Table 1 ).
Participants were divided into tertiles according to plasma LRG1 levels to visualize baseline characteristics (Supplemental Table 2 ). Those with a baseline LRG1 level in the highest tertile were older, more likely to be female and an ethnic minority, had a longer diabetes duration, a higher BMI and SBP, and, notably, had a higher ACR level and lower eGFR. As expected, participants with a higher level of plasma LRG1 had a higher level of CRP.
Multivariable linear regression suggested that plasma LRG1 levels were independently associated with sex, ethnicity, smoking, high-density lipoprotein cholesterol, triacylglycerol, eGFR, and ACR at baseline. Adjustment for CRP attenuated the association of LRG1 with ACR but not its association with eGFR (Supplemental Table 3 , models 4 and 5).
Baseline plasma LRG1 level independently predicted albuminuria progression
The transition of albuminuria categories from baseline to the 3-year follow-up is presented in Table 1 . Of 697 participants with normoalbuminuria at baseline, 140 (20%) progressed to microalbuminuria or macroalbuminuria, whereas among 364 participants with microalbuminuria at baseline, 81 (22%) progressed to macroalbuminuria. On the other hand, 102 (28%) participants with microalbuminuria at baseline had albuminuria regression. Noteworthy, participants with albuminuria progression had significantly higher LRG1 levels (median, 17.7 mg/mL; IQR, 12.3 to 24.7 mg/mL) than those with stable albuminuria (median, 15.0 mg/mL; IQR, 11.0 to 20.8 mg/mL) and participants with albuminuria regression (median, 14.3 mg/mL; IQR, 10.4 to 21.3 mg/mL; Bonferroniadjusted P = 0.005 and P , 0.0001, respectively; Table 2 ].
We combined 738 participants with stable albuminuria and 102 participants with albuminuria regression as controls in the primary analysis. Compared with controls, participants with albuminuria progression were older and had a higher BMI and lower eGFR level at baseline. They were more likely on insulin treatment and to be of Malay ethnicity. Logistic regression models showed that a 1-SD increment in natural log-transformed plasma LRG1 was associated a 1.38-fold increased risk [95% confidence interval (CI), 1.16 to 1.63; P , 0.0001) for albuminuria progression after adjustment for age, sex, ethnicity, diabetes duration, smoking, BMI, HbA1c, SBP, and lipids profile. Further adjustment for baseline eGFR and ACR attenuated the odds ratio (OR), but the association was still statistically significant (OR, 1.21; 95% CI, 1.01 to 1.45; P = 0.035). In the fully adjusted model (Table 3) , a 1-SD increment in plasma LRG1 was associated with a 1.26-fold (95% CI, 1.04 to 1.53; P = 0.018) higher risk for albuminuria progression.
Plasma LRG1 predicted CKD progression beyond baseline eGFR and ACR
Of 1066 participants in the CKD progression analysis, 88 were classified as having CKD progression (Table 4) . Those with CKD progression had an average 59% eGFR decline from baseline compared with a 3.9% eGFR reduction in the control group in the same period. Progressors had a longer diabetes duration; a higher HbA1c, SBP, and ACR; and a lower eGFR level at baseline. Notably, baseline plasma LRG1 levels were significantly higher in participants with CKD progression (median, 19.9 mg/mL; IQR, 14.7 to 27.8 mg/mL) compared with those with stable renal function (median, 15.1 mg/mL; IQR, 11.0 to 21.0 mg/mL; P , 0.0001). Multivariable logistic regression models suggested that plasma LRG1 level was independently associated with CKD progression after adjustment for demographic and metabolic risk factors, as well as baseline eGFR and ACR. Additional adjustment for renin-angiotensin system blocker and insulin usage as well as CRP levels did not materially change the outcome. In the fully adjusted model (Table 5 ), a 1-SD increment in natural log-transformed LRG1 was associated with a 1.48-fold (95% CI, 1.04 to 2.11; P = 0.032) increased risk for CKD progression.
Sensitivity analyses for association of plasma LRG1 with ACR progression
Given that nondiabetic causes may have been involved in the progression from normoalbuminuria to microalbuminuria and that macroalbuminuria is highly correlated with typical diabetic glomerulopathy on renal biopsy (2, 34, 35), we stratified participants according to baseline albuminuria categories to analyze the association of plasma LRG1 with normoalbuminuria to microalbuminuria and microalbuminuria to macroalbuminuria progression separately (Supplemental Table 4 ). The association of plasma LRG1 with progression from microalbuminuria to macroalbuminuria was stronger than its association with progression from normoalbuminuria to microalbuminuria (OR, 1.51; 95% CI, 1.04 to 2.18, P = 0.029 vs OR, 1.09; 95% CI, 0.86 to 1.37, P = 0.486; Supplemental Table 5 ).
Cognizant that there are considerable intraindividual variations in albuminuria (2), we performed a subpopulation analysis in 180 participants with three ACR readings collected separately within 6 months near enrollment and follow-up date (Supplemental Table 6 ). The geometric average of three ACR readings was used to determine changes in albuminuria categories. A 1-SD increment in natural log-transformed LRG1 in this subpopulation was associated with a 1.61-fold (95% CI, 0.96 to 2.70; P = 0.074) increased risk for albuminuria progression after adjustment for traditional risk factors, including baseline eGFR and ACR (Supplemental Table 7 ).
Exclusion of 102 participants with albuminuria regression slightly attenuated the association of plasma LRG1 with albuminuria progression (OR, 1.21; 95% CI, 1.00 to 1.48, P = 0.055 vs OR, 1.26; 95% CI, 1.04 to 1.53, P = 0.018 as observed in primary analysis). Although female participants had higher LRG1 levels than males [median, 17.3 (IQR, 12.6 to 24.2) mg/mL vs 14.3 (IQR, 10.5 to 19.8) mg/mL, P , 0.0001], plasma LRG1 did not interact with sex in its association with either albuminuria progression (P-interaction = 0.31) or CKD progression (P-interaction = 0.85). Neither did LRG1 interact with ethnicity in its relationship with DKD progression.
Association of urine LRG1 with DKD progression
In binary correlation analysis, urine LRG1 level was correlated with urine ACR (Pearson r = 0.44, P , 0.0001) and eGFR levels (Pearson r = 20.14, P , 0.0001). It was weakly but significantly correlated with plasma LRG1 level (Pearson r = 0.15, P , 0.0001). In multivariable analysis, urine LRG1 was independently associated with sex, diabetes duration, HbA1c, SBP, plasma CRP, and urine ACR after adjustment for multiple demographic and metabolic covariates.
Urine LRG1 level was higher in participants with ACR progression compared with controls [median, 57 (IQR, 26 to 155) mg/mL vs 40 (IQR, 13 to 107) mg/mL; P , 0.001].
Logistic regression suggested that participants with a higher urine LRG1 level had a high risk for ACR progression (OR, 1.21; 95% CI, 1.00 to 1.46; P = 0.056, per 1-SD log-LRG1) after adjustment for all the covariates in Table 3 . Interestingly, further analysis revealed that the difference in urine LRG1 levels between ACR progressors and nonprogressor controls was more pronounced in those with normoalbuminuria at baseline [median, 28 (IQR, 11 to 77) mg/mL vs 47 (IQR, 16 to 120) mg/mL; P , 0.0001] than that in participants with microalbuminuria at baseline [median, 79 (IQR, 24 to 192) mg/mL vs 77 (IQR, 36 to 273) mg/mL; P = 0.042]. In multivariable logistic regression, baseline urine LRG1 independently predicted normoalbuminuria to microalbuminuria progression but not microalbuminuria to macroalbuminuria progression above traditional risk factors (Supplemental Table 8 ).
Urine LRG1 was higher in participants with CKD progression as compared with controls [median, 47 (IQR, 14 to 122) mg/mL vs 248 (IQR, 77 to 679) mg/mL; P , 0.0001]. It was independently associated with CKD progression after adjustment for multiple demographic and cardiometabolic risk factors (OR, 2.46; 95% CI, 1.70 to 3.55; P , 0.0001, per 1-SD log-LRG1). The association remained significant after further adjustment for eGFR (OR, 2.33; 95% CI, 1.58 to 3.42; P , 0.0001). However, the association of urine LRG1 with CKD progression was significantly attenuated after additional adjustment for urine ACR (OR, 1.27; 95% CI, 0.86 to 1.89; P = 0.616).
Added value for prediction of DKD progression by plasma LRG1 above traditional risk predictors Forward logistic regression suggested that BMI, baseline eGFR, ACR, and insulin usage were traditional predictors for albuminuria progression. Adding plasma LRG1 significantly increased net reclassification improvement (0.323; 95% CI, 0.082 to 0.564; P = 0.009) and integrated discrimination improvement (0.018; 95% CI, 0.0004 to 0.035; P = 0.045), although area under the curve did not change materially (mean 6 SD, 0.719 6 0.020 vs 0.722 6 0.019). Traditional risk factors (age, sex, ethnicity, usage of the renin-angiotensin system, HbA1c, SBP, ACR, and eGFR) accurately predicted CKD progression (area under the curve = 0.912). Adding plasma LRG1 did not improve area under the curve, net reclassification improvement, and integrated discrimination improvement for prediction of CKD outcome above traditional risk factors.
Discussion
In this prospective study, we found that plasma LRG1 level independently predicted both albuminuria and CKD progression in individuals with T2DM. Of note, the association of plasma LRG1 with DKD progression is independent of traditional risk factors, including glycemic control, hypertension, and baseline eGFR and albuminuria levels, suggesting that LRG1 may potentially play a role in the pathophysiologic pathway leading to DKD progression.
Enhanced angiogenesis is a feature of diabetic glomerulopathy (21) . Changes in vascular growth factors may lead to glomerular endothelial cell proliferation, destabilization, and subsequently marked albuminuria (21, 36) . LRG1 is mitogenic to endothelial cells and promotes angiogenesis in the presence of TGF-b (15) . We postulate that the elevated level of LRG1 may be involved in structural and/or functional abnormalities in glomerular endothelial cells and lead to impaired filtration barrier, albumin leakage, and decline in filtration rate in diabetic patients. In addition, TGF-b signaling is often activated under enhanced metabolic flux and is considered the final common pathway in the development and progression of nephropathy (26) . It is possible that LRG1 may also be involved in other features of diabetic nephropathy such as mesangial expansion and extracellular matrix deposition by binding to TGF-b accessory receptor endoglin and function as a regulator of the TGF-b signaling pathway in diabetic kidney. Moreover, endoglin is an important regulator of endothelial nitric oxide synthase stability (37) . Thus, interaction between LRG1 and endoglin may lead to alteration in nitric oxide production and changes in the tone of microvascular capillaries, which may affect the integrity of the glomerular filtration barrier. DKD is also associated with persistent overexpression of inflammation-associated genes and pathways (19) . LRG1 has been proposed as a marker for inflammatory diseases (12) (13) (14) . Indeed, plasma LRG1 level was independently associated with CRP, the established marker for systemic inflammation, at a cross-sectional level in our study (Supplemental Table 3 ). However, the prediction of albuminuria progression by LRG1 did not change materially after adjustment for CRP in the current prospective study (Tables 3 and 5 ). These data suggest that the relationship between LRG1 and DKD progression may be independent of inflammation.
The strengths of the current study include a large sample size and its prospective nature in study design. Several weaknesses should be mentioned. First and importantly, we do not have data to suggest the biological link between a higher plasma LRG1 level and DKD progression in the current study. Although LRG1 has been implicated in angiogenesis by regulating TGF-b signaling, it may have other biological functions depending on the pathophysiological context. The intrarenal expression of LRG1 (if any), its relationship with circulating LRG1, and its interactions with endoglin/TGF-b, as well as its crosstalk with other established vascular factors such as vascular endothelial growth factor and angiopoietin in different compartments of the diabetic kidney, should be determined in future studies. Therefore, data from our current study can only be taken as hypothesis generation. Second, we measured urine albumin level and eGFR only once at baseline and the follow-up study, respectively. Considerable intraindividual variation in albuminuria and eGFR levels may affect classification of DKD progression (2). However, our small subpopulation analysis with multiple ACR measurements resulted in similar outcomes as that in primary analysis. On the other hand, a higher random ACR and eGFR measurement variation may reduce the statistical power and tend to lead to a false-negative outcome. In this sense, the one-time measurement may not be a major concern for the positive findings in our current study. Also, it should be mentioned that we measured creatinine by the enzymatic method. Although it is traceable to isotope dilution mass spectrometry, it is not ideal in terms of accuracy. Third, although albuminuria progression and rapid eGFR decline are established risk factors for progression to ESRD and mortality (2, 31) , they are only intermediate outcomes.
Future studies are warranted to elucidate the relationship between LRG1 and hard outcomes, including ESRD. Fourth, the 3-year follow-up duration may be relatively short. The relationship between LRG1 and DKD progression should be further studied in the next longer follow-up.
Conclusion
Plasma LRG1 is independently associated with both albuminuria and CKD progression in participants with T2DM. Our data suggest that, to our knowledge, LRG1 may be a novel factor that plays a role in the pathophysiology of DKD.
